AFMD
|Affimed NV
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
2.98M
Volume
Open
Previous Close
52-Week High
USD 8.95
52-Week Low
USD 0.07
About Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...
Sector:Healthcare
Industry:Biotechnology
CEO:
Employees:76
Headquarters:Mannheim, Germany
Website:www.affimed.com
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions